Status:
COMPLETED
Disease Management Platform for Heart Failure (DMP-HF)
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
AstraZeneca
Conditions:
Heart Failure
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
AMAZE™ is a disease management platform (DMP) designed to educate patients about heart failure, help engage them in healthy behaviors and assist them in taking their medications as prescribed. This st...
Detailed Description
Heart failure (HF) management and readmissions remain at the top of the list of complex topics in cardiovascular medicine in the United States. Current system-wide programs to curb HF-related hospital...
Eligibility Criteria
Inclusion
- Adults (\>21 years) admitted to MGH Cardiology services (Ellison 10 and 11) with a primary diagnosis of heart failure \[HFrEF(\<40%), HFmEF(40-49%) HFpEF(≥50%)\] (or to BWH Cardiology services for BWH EHR-based controls)
- Has a smartphone or iPad and is willing to enter health metrics into DMP App and email willing to use for the study
- Access to the internet
- Established or with plan to establish primary cardiologist at MGH (or at BWH for BWH EHR-based controls)
- Discharged home or to self-care (with or without home services)
Exclusion
- Moderate or severe cognitive impairment
- Non-English-speaking
- Palliative management only (comfort measures)
- Does not own a smartphone or iPad (not considered for EHR-based controls)
- Incarcerated
Key Trial Info
Start Date :
March 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 16 2021
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04782973
Start Date
March 11 2021
End Date
November 16 2021
Last Update
March 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114